Transposon Therapeutics, Inc. is developing TPN-101 (also known as Censavudine) and other LINE-1 reverse transcriptase inhibitors for the treatment of rare neurodegenerative diseases such as progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Aicardi-Goutières Syndrome (AGS).
Location: United States, Connecticut, Westport
Investors 2
| Date | Name | Website |
| 26.10.2023 | Lumira Ven... | lumiravent... |
| 26.09.2022 | Canaan Par... | canaan.com |
Mentions in press and media 6
| Date | Title | Description |
| 28.05.2025 | Transposon Announces TPN-101 Selected for Inclusion in the Phase 2/3 HEALEY ALS Platform Trial, Building on the Success of Phase 2 Study in C9orf72-related ALS | In the Phase 2 Study of TPN-101 in patients with C9orf72-related ALS, TPN-101 showed clinical benefits on key clinical outcome measures, including slow vital capacity and the ALSFRS-R TPN-101 also had lowering effects on key biomarkers of n... |
| 24.07.2024 | Transposon Announces Final Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia | TPN-101 treatment reduced the rate of decline of Vital Capacity by 50% compared to placebo after 24 weeks, an objective respiratory measure that correlates with mortality in patients with ALS Treatment with TPN-101 also showed a slowing of ... |
| 21.05.2024 | Transposon Receives US FDA Fast Track Designation for TPN-101 for Progressive Supranuclear Palsy | Designation Supports Accelerated Drug Development for PSP TPN-101 is the First PSP Treatment to Reduce NfL and IL-6 Levels, Key Biomarkers of Neurodegeneration and Neuroinflammation in PSP SAN DIEGO, May 21, 2024 /PRNewswire/ -- Transposon ... |
| 13.02.2024 | Transposon Announces Final Results from a Phase 2 Study of its LINE-1 Reverse Transcriptase Inhibitor TPN-101 for the Treatment of Progressive Supranuclear Palsy and Interim Results from a Phase 2 Stu... | TPN-101 is the first PSP treatment to reduce NfL and IL-6 levels, key biomarkers of neurodegeneration and neuroinflammation in PSP Participants treated with TPN-101 for the entire 48-week study in PSP showed a stabilization of their clinica... |
| 13.02.2024 | Transposon Announces Final Results from a Phase 2 Study of its LINE-1 Reverse Transcriptase Inhibitor TPN-101 for the Treatment of Progressive Supranuclear Palsy and Interim Results from a Phase 2 Stu... | SAN DIEGO, Feb. 12, 2024 /PRNewswire/ -- Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases including Alzheimer's ... |
| 14.11.2023 | Transposon Announces Interim Results from a Phase 2 Study of TPN-101 for the Treatment of Progressive Supranuclear Palsy to be Presented at the AD/PD™ 2024 International Conference on Alzheimer's and ... | 24-Week data show TPN-101 is the first treatment for PSP to reduce NfL levels, a key biomarker of neurodegeneration in tauopathies such as PSP and Alzheimer's disease |